The CHD6 Knockout Raji Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population in which the CHD6 gene has been disrupted in the Raji human B lymphoblastoid cell line. This product provides a loss-of-function model for investigating the functional consequences of CHD6 deficiency in a B-cell context. The polyclonal nature preserves cellular heterogeneity and is suitable for pooled knockout studies, offering a robust platform for examining gene function without the biases associated with single-cell clonal isolation.
The Raji cell line, derived from an EBV-positive Burkitt??s lymphoma, is a well-characterized model of B lymphocytes. These cells maintain key characteristics of B-cell biology, including active antibody production and antigen presentation capabilities, and are widely used in immunology and cancer research. As a lymphoblastoid cell line, Raji cells exhibit rapid proliferation and are amenable to genetic manipulation, making them an ideal host for knockout studies. The EBV-positive background additionally allows exploration of viral latency and its interplay with host chromatin remodelers like CHD6.
CHD6 encodes a chromodomain-helicase-DNA-binding protein that serves as a central component of chromatin remodeling and transcriptional regulation. Mechanistically, CHD6 modulates gene expression by altering nucleosome positioning and interacting with key transcriptional regulators. Upstream, CHD6 activity is influenced by transcription factors EGR1, NAB2, and SP1. CHD6 associates with NAB2, histone H3, RNA polymerase II, and the deacetylase HDAC1, forming complexes that fine-tune chromatin structure. Downstream, CHD6 regulates the expression of critical cell cycle and oncogenic genes, including CDKN1A, CCND1, and MYC, thereby impacting proliferation and survival programs. Additionally, CHD6 contributes to DNA damage repair pathways, integrating chromatin dynamics with genome stability.
In the context of B-cell lymphomas, CHD6 deregulation has been implicated in tumorigenesis, with links to melanoma and other cancers. The Raji CHD6 knockout model enables dissection of CHD6’s specific functions in lymphomagenesis, including its roles in transcriptional reprogramming and DNA damage responses. By eliminating CHD6 in an EBV-positive Burkitt??s lymphoma background, researchers can investigate how chromatin remodeling defects alter B-cell proliferation, survival, and interactions with the tumor microenvironment, offering insights into novel therapeutic vulnerabilities.
This polyclonal knockout cell population is suitable for a wide array of research applications, including functional studies of CHD6 in B-cell biology, chromatin remodeling mechanisms, and lymphoma pathogenesis. It supports drug target validation and phenotypic screening of CHD6-dependent pathways. Experimentally, the cells can be characterized using western blotting for CHD6, RT-qPCR for target genes like MYC and CDKN1A, RNA-seq for transcriptome-wide analysis, ChIP-qPCR for histone modifications, flow cytometry for B-cell surface markers, and proliferation or apoptosis assays. For further details or assistance with experimental design, please contact Ascent Research.
